Chicory RG-I modulates gut microbiota and immune responses in healthy adults
The provided text contains no numerical results; effect direction cannot be determined from the available material.
| Endpunkt | Grad | Richtung | Effekt | Studien |
|---|---|---|---|---|
| Gut microbiota composition (bifidobacteria abundance) | D | — Unzureichend | não reportado | — |
| Immune response markers | D | — Unzureichend | não reportado | — |
| Fecal short-chain fatty acids (SCFA) | D | — Unzureichend | não reportado | — |
Kontext
RG-I is a structurally complex pectin domain with putative prebiotic and immunomodulatory properties. Prior trials using 300 mg and 1500 mg/day of RG-I from other sources demonstrated microbiota modulation in healthy adults. This trial tests 500 mg/day of chicory-derived RG-I (chRG-I), a structurally distinct source and by-product of industrial inulin extraction.
Was die Studie zeigte
The available text contains no results section with numerical data. No absolute values, relative values, 95% CIs, or effect sizes can be extracted. Effect direction remains undetermined based on the supplied material.
Wie es durchgeführt wurde
Randomized controlled trial (RCT), as stated in the title and keywords. Sample size, intervention duration, inclusion/exclusion criteria, and randomization procedures are not described in the available text.
Effektgröße
Not reported in the available text. No effect size with CI can be calculated or extracted.
Einschränkungen
The full results and discussion sections were not provided — only the introduction is present, repeated three times. No risk-of-bias tool (RoB 2, ROBINS-I) could be applied. Critical appraisal is structurally compromised by the absence of primary data.
In der klinischen Praxis
No clinical recommendation can be issued based on the available material. Clinicians must not extrapolate clinical effects from studies whose results are unavailable for review.
Was noch fehlt
Complete trial results are required — including relative abundance data for bifidobacteria, immune markers, fecal SCFA, and adverse events — before any clinical inference is possible.